Kardigan, Inc. IPO - What You Need to Know

Thinking about buying into the Kardigan, Inc. IPO? It is exciting to get in early, but before you invest, let’s break down what this company actually does in plain English.

Here is your guide to the Kardigan IPO.

1. What does this company actually do?

Kardigan is a biotech company focused on research. They develop new medicines for serious heart conditions. They use a proprietary platform called Prolaio. This system uses wearable sensors and AI to collect real-time health data from patients at home. This helps Kardigan design faster, more efficient clinical trials by monitoring patients outside of hospitals.

2. What is their "product"?

They have three drugs in development:

• Danicamtiv: A treatment for a specific genetic heart muscle disease.
• Ataciguat: A daily pill to slow down heart valve disease.
• Tonlamarsen: A monthly injection for severe high blood pressure that resists standard treatments.

3. How do they make money?

Right now, they don’t. They have zero sales and have never made a profit. They are in the research phase, spending massive amounts of money to test drugs. As of March 31, 2026, they had an "accumulated deficit" of $337.2 million. This means they have spent $337.2 million more than they have ever earned.

4. What will they do with the money from this IPO?

They plan to use the cash to fund clinical trials and develop their Prolaio technology. They had $287 million in cash as of March 31, 2026, but they are spending it quickly. They reported a loss of $56.1 million for the three months ending March 31, 2026. This IPO helps them extend their "runway"—the time they have to reach a breakthrough before needing more cash.

5. What are the main risks?

Biotech investing is high-stakes. Here is what you should know:

• The "All-or-Nothing" Risk: Success depends entirely on whether their drugs pass clinical trials and win FDA approval. If a trial fails, the company’s value could drop significantly. They have no other products to fall back on.
• Dilution: To keep running, they will likely sell more shares. If they issue more shares, your ownership percentage shrinks, which can lower the stock price.
• Giving Away the Farm: They may sign deals giving other companies rights to their technology. This could limit their future profits.
• Cash Safety: They keep large amounts of cash in banks. If those banks fail, Kardigan might lose access to the money needed for their trials.
• "Emerging Growth" Status: As an emerging growth company, Kardigan provides less detailed financial reporting than larger, established companies.
• Stock Splits: They plan a "reverse stock split" before the IPO. This reduces the total number of shares and increases the price per share, but it does not change the company's actual value or your share of it.

6. Who’s running the company?

The CEO is Tassos Gianakakos. He and his team are industry veterans. They previously worked at MyoKardia, where they helped develop and gain approval for a heart medication before the company was acquired. A leadership team with a track record of navigating the FDA is a major part of their strategy.

7. The Details

• Ticker: KARD on the Nasdaq.
• Insider Participation: They reserved up to 5% of shares for their own employees and directors. It is usually a good sign when the people building the company invest their own money.

Disclaimer: I am an AI, not a financial advisor. Biotech IPOs are extremely volatile. A company can lose a significant portion of its value overnight if a drug trial fails. Never invest money you cannot afford to lose. Before you buy, read the "Risk Factors" section of their S-1 filing on the SEC website—it is the most important part of the document.